-
Je něco špatně v tomto záznamu ?
HER-3 molecular classification, expression of PD-L1 and clinical importance in breast cancer
Libor Stanek, Robert Gurlich, Adam Whitley, Petra Tesarova, Zdenek Musil, Lucie Novakova
Jazyk angličtina Země Slovensko
Typ dokumentu práce podpořená grantem, přehledy, klinická studie
- MeSH
- amplifikace genu MeSH
- antigeny CD274 biosyntéza MeSH
- cytogenetické vyšetření MeSH
- dospělí MeSH
- erbB receptory škodlivé účinky MeSH
- imunoanalýza MeSH
- lidé středního věku MeSH
- lidé MeSH
- proteosyntéza * MeSH
- senioři MeSH
- triple-negativní karcinom prsu * etiologie genetika imunologie patofyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- Publikační typ
- klinická studie MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Receptors of the large HER family play an important role in breast cancer, which is undergoing a gradual development in connection with biological development, both in the fi eld of diagnostics and therapy. Dimerization of HER-2 with other HER members, such as HER-3, is the biggest driver of tumor cell growth and survival. Numerous studies show that HER-3 gene overexpression correlates with poor prognosis. However, other studies have shown HER-3 overexpression to be a positive prognostic factor. HER-3 may confer resistance to certain EGFR or HER-2 receptor therapeutics. An interesting fact, however, is that HER-3 expression can serve as a marker in immunotherapy for triple-negative breast cancer (TNBC). It is thought to be involved not only in cell survival and proliferation, but also in the regulation of PD-L1 expression. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence of tumor-infi ltrating lymphocytes and a number of factors with poor prognosis such as young age, hormone receptor negativity, and high HER-2 expression and proliferation index. Our results showed amplifi cation of HER-3 (CERB3) in 2 out of a sample of 20 patients with TNBC, and 13 of 20 HER-2-positive patients. PD-L1 expression was demonstrated in 3 out of 13 HER-3-positive patients and 2 out of 2 HER-3-positive TNBC patients. There was a strong correlation between positive HER-3 and PD-L1 TNBC expression (p = < 0.001). Thus, the view of the HER-3 receptor will be much more complex, and the overexpression of this receptor appears to have both negative and positive prognostic and clinical impacts (Tab. 1, Ref. 17).
1st Faculty of Medicine Charles University Prague Institute of Oncology Prague Czechia
3rd Faculty of Medicine Charles University Prague Department of Anatomy Prague Czechia
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22026120
- 003
- CZ-PrNML
- 005
- 20221219014421.0
- 007
- ta
- 008
- 221103s2022 xo fs 000 0|eng||
- 009
- AR
- 024 0_
- $a 10.4149/BLL_2022_115 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Staněk, Libor $7 xx0141390 $u Department of Surgery, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czechia $u Third Faculty of Medicine, Charles University in Prague, Department of Histology and Embryology, Prague, Czechia
- 245 10
- $a HER-3 molecular classification, expression of PD-L1 and clinical importance in breast cancer / $c Libor Stanek, Robert Gurlich, Adam Whitley, Petra Tesarova, Zdenek Musil, Lucie Novakova
- 504 __
- $a Literatura
- 520 3_
- $a Receptors of the large HER family play an important role in breast cancer, which is undergoing a gradual development in connection with biological development, both in the fi eld of diagnostics and therapy. Dimerization of HER-2 with other HER members, such as HER-3, is the biggest driver of tumor cell growth and survival. Numerous studies show that HER-3 gene overexpression correlates with poor prognosis. However, other studies have shown HER-3 overexpression to be a positive prognostic factor. HER-3 may confer resistance to certain EGFR or HER-2 receptor therapeutics. An interesting fact, however, is that HER-3 expression can serve as a marker in immunotherapy for triple-negative breast cancer (TNBC). It is thought to be involved not only in cell survival and proliferation, but also in the regulation of PD-L1 expression. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence of tumor-infi ltrating lymphocytes and a number of factors with poor prognosis such as young age, hormone receptor negativity, and high HER-2 expression and proliferation index. Our results showed amplifi cation of HER-3 (CERB3) in 2 out of a sample of 20 patients with TNBC, and 13 of 20 HER-2-positive patients. PD-L1 expression was demonstrated in 3 out of 13 HER-3-positive patients and 2 out of 2 HER-3-positive TNBC patients. There was a strong correlation between positive HER-3 and PD-L1 TNBC expression (p = < 0.001). Thus, the view of the HER-3 receptor will be much more complex, and the overexpression of this receptor appears to have both negative and positive prognostic and clinical impacts (Tab. 1, Ref. 17).
- 650 _7
- $a dospělí $7 D000328 $2 czmesh
- 650 _7
- $a senioři $7 D000368 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 _7
- $a lidé středního věku $7 D008875 $2 czmesh
- 650 _7
- $a erbB receptory $x škodlivé účinky $7 D066246 $2 czmesh
- 650 _7
- $a antigeny CD274 $x biosyntéza $7 D060890 $2 czmesh
- 650 17
- $a proteosyntéza $7 D014176 $2 czmesh
- 650 17
- $a triple-negativní karcinom prsu $x etiologie $x genetika $x imunologie $x patofyziologie $7 D064726 $2 czmesh
- 650 _7
- $a amplifikace genu $7 D005784 $2 czmesh
- 650 _7
- $a imunoanalýza $7 D007118 $2 czmesh
- 650 _7
- $a cytogenetické vyšetření $7 D020732 $2 czmesh
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 655 _7
- $a přehledy $7 D016454 $2 czmesh
- 655 _7
- $a klinická studie $7 D000068397 $2 czmesh
- 700 1_
- $a Gürlich, Robert, $d 1964- $7 xx0000272 $u Department of Surgery, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Whitley, A $7 _AN117976 $u Department of Surgery, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Tesařová, Petra, $d 1961- $7 xx0102804 $u First Faculty of Medicine, Charles University in Prague, Institute of Oncology, Prague, Czechia
- 700 1_
- $a Musil, Zdeněk $7 xx0107856 $u Third Faculty of Medicine, Charles University in Prague, Department of Anatomy, Prague, Czechia
- 700 1_
- $a Nováková, Lucie $7 _AN042558 $u Third Faculty of Medicine, Charles University in Prague, Department of Histology and Embryology, Prague, Czechia
- 773 0_
- $t Bratislavské lekárske listy $x 0006-9248 $g Roč. 123, č. 10 (2022), s. 719-723 $w MED00000845
- 856 41
- $u http://www.elis.sk/download_file.php?product_id=7755&session_id=5hob67buame1h4jbqk1qin6737 $y plný text volně přístupný
- 910 __
- $a ABA008 $b online $c 1067 $y p $z 0
- 990 __
- $a 20221101161338 $b ABA008
- 991 __
- $a 20221219014408 $b ABA008
- 999 __
- $a ok $b bmc $g 1856112 $s 1177424
- BAS __
- $a 3
- BMC __
- $a 2022 $b 123 $c 10 $d 719-723 $i 0006-9248 $m Bratislavské lekárske listy $x MED00000845
- LZP __
- $c NLK189 $d 20221219 $a NLK 2022-22/kv
